Advertisement
Advertisement
U.S. Markets close in 1 hr 38 mins
Advertisement
Advertisement
Advertisement
Advertisement

Navidea Biopharmaceuticals, Inc. (NAVB)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.1028-0.0372 (-3.26%)
As of 02:21PM EST. Market open.
Advertisement

Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue
Suite 240
Dublin, OH 43017-3552
United States
614 793 7500
http://www.navidea.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Jed A. LatkinCEO, COO, CFO & Director739.99kN/A1974
Dr. Michael Stanley Rosol Ph.D.Chief Medical Officer282.45kN/A1969
Erika GibsonDirector of Fin. & Admin.N/AN/AN/A
Mr. William J. ReganChief Compliance OfficerN/AN/A1952
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Corporate Governance

Navidea Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement